We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. ANI Pharmaceuticals (ANIP - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
ANI Pharmaceuticals is one of 890 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ANI Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ANIP's full-year earnings has moved 12.1% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, ANIP has gained about 0.8% so far this year. Meanwhile, stocks in the Medical group have lost about 8.5% on average. This means that ANI Pharmaceuticals is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Adlai Nortye Ltd. Sponsored ADR (ANL - Free Report) . The stock is up 833.1% year-to-date.
Over the past three months, Adlai Nortye Ltd. Sponsored ADR's consensus EPS estimate for the current year has increased 45.8%. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, ANI Pharmaceuticals belongs to the Medical - Biomedical and Genetics industry, a group that includes 435 individual companies and currently sits at #144 in the Zacks Industry Rank. Stocks in this group have lost about 1.6% so far this year, so ANIP is performing better this group in terms of year-to-date returns. Adlai Nortye Ltd. Sponsored ADR is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on ANI Pharmaceuticals and Adlai Nortye Ltd. Sponsored ADR as they attempt to continue their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. ANI Pharmaceuticals (ANIP - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
ANI Pharmaceuticals is one of 890 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ANI Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ANIP's full-year earnings has moved 12.1% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, ANIP has gained about 0.8% so far this year. Meanwhile, stocks in the Medical group have lost about 8.5% on average. This means that ANI Pharmaceuticals is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Adlai Nortye Ltd. Sponsored ADR (ANL - Free Report) . The stock is up 833.1% year-to-date.
Over the past three months, Adlai Nortye Ltd. Sponsored ADR's consensus EPS estimate for the current year has increased 45.8%. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, ANI Pharmaceuticals belongs to the Medical - Biomedical and Genetics industry, a group that includes 435 individual companies and currently sits at #144 in the Zacks Industry Rank. Stocks in this group have lost about 1.6% so far this year, so ANIP is performing better this group in terms of year-to-date returns. Adlai Nortye Ltd. Sponsored ADR is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on ANI Pharmaceuticals and Adlai Nortye Ltd. Sponsored ADR as they attempt to continue their solid performance.